Innocube

What Innocube does

InnoCube (이노큐브) is a Seoul-based bio healthcare accelerator established in September 2021 as a subsidiary of Handok (한독), the Korean pharmaceutical company, which retains 72.97% ownership. Operating from the Handok Future Complex in Seoul's Magok district, InnoCube runs a 3-year minimum incubation program targeting early-stage biotech, pharmaceutical, medical device, diagnostics, and digital health startups, with typical tickets of 500 million to 2 billion KRW per company. As of the most recent reporting it had invested approximately 50 billion KRW across 10 portfolio companies, 7 of which are in residence, and includes EPD Bio Therapeutic (acquired by Handok affiliate J제넥신 in July 2023) among its realized outcomes. Its operating reference points include international bio accelerators such as FutuRx, J&J Jlabs, and RMGP.

The core offering is a total incubation package combining research space, shared laboratories, high-end equipment, management consulting, financing advisory, and the proprietary CUBING (CUBE-Incubating Program) curriculum. Underlying platform components include a Scientific Advisory Board drawn from MIT, Harvard, KAIST, Seoul National University, and Yonsei, providing technical and clinical diligence across bioinformatics, immunology, and clinical research. Technology exposure is indirect and portfolio-driven rather than proprietary: BNJ Bio Pharma applies AI to drug discovery, while K-Main (케이마인) develops AI-enabled portable fluorescence diagnostic devices. A TIPS operator designation granted in April 2023 gives the accelerator access to government-backed startup programs.

The business model is a hybrid of fund management and equity participation. InnoCube manages InnoHealth Fund 1 (15 billion KRW, formed March 2023) and the Sevrance-InnoCube Venture Investment Fund (90 billion KRW target, formed December 2023 with Yonsei Severance Hospital), generating recurring management fees and equity stakes in portfolio companies, with a 3-year milestone-based incubation horizon. Go-to-market is anchored by Handok's pharmaceutical network for downstream commercialization and exit pathways, augmented by partnerships with CreActive Health (venture studio, July 2023) and GE Healthcare Korea (MOU, July 2024). Pricing is not publicly disclosed and revenue is not reported separately; monetization is expected to be a mix of fund management fees, facility/service fees from resident companies, and long-tail exit proceeds.

Name

Innocube

Legal name

주식회사 이노큐브

Website

https://innocuve.com

Company type

Private

Founded year

2021

Operating status

Operating

Short description

InnoCube (이노큐브) is a Seoul-based bio healthcare accelerator founded in September 2021 by Handok, operating a 3-year minimum incubation program for early-stage biotech, pharmaceutical, medical device, diagnostics, and digital health startups, with approximately 50 billion KRW deployed across 10 portfolio companies (7 resident) via its venture funds.

Ownership category

akta.pro rank

Product category

Bio Healthcare Startup Accelerator

NAICS

Portfolio Management and Investment Advice (523940), Securities, Commodity Contracts, and Other Financial Investments and Related Activities (523)

SIC

Investment Advice (6282)

akta.pro primary industry

Accelerators & Incubators (Investor-Operated) (FSANAAAM)

Keywords

• Bio healthcare accelerator
• Startup incubation services
• Venture capital fund
• Biotech shared laboratory
• Biopharmaceutical incubation

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Infrastructure, Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Investment Returns from Portfolio Companies: InnoCube generates returns through equity investments in bio healthcare startups. Investment companies receive 500 million to 2 billion KRW per company with milestone-based funding over 3-year minimum incubation period. Notable exit achieved through EPD Bio Therapeutic being acquired by J不正证券.
2. Accelerator Services and Facility Fees: Provides subsidized research space and office facilities to resident companies at nominal cost levels, enabling startups to allocate most investment capital to R&D activities.
3. Fund Management Fees: Operates venture funds including InnoHealth Fund 1 (15 billion KRW) and Sevrance-InnoCube Venture Investment Fund (90 billion KRW), generating management fees from fund operations.

Pricing tiers

Go-to-market motion3 records

Distribution channels1 record

Marketing channels6 records

Core offering

Innocube is a bio healthcare-focused startup accelerator that provides total services including shared research laboratory space, office facilities, high-end research equipment, financing advisory, development strategy support, and management infrastructure to early-stage bio healthcare startups. Operating within Handok Future Complex in Seoul's Magok district, the company invests 500 million to 2 billion KRW per portfolio company over a minimum 3-year incubation period while also operating venture funds totaling over 100 billion KRW (Inno Health Fund 1 and Severance-InnoCube Venture Investment Fund).

Product overview

Innocube는 대한민국 대표 바이오 헬스케어 엑셀러레이터로, 바이오 헬스케어 스타트업에게 연구공간 대여, 프로젝트 개발 논의, 경영 지원 등의 토탈 서비스를 제공한다. 주요 서비스로는 Open Lab. 및 사무공간, 공용연구실, 고가장비실(BIACORE T200, LCMS 등), 성장 단계별 Financing 자문, 개발 전략 및 외부 협업 지원, 경영지원 인프라도 제공한다. CUBING 프로그램을 통해 체계적인 교육과 멘토링을 제공하고, CONNECT & NETWORKING을 통해 네트워킹 기회를 제공한다. 이스라엘의 FutuRX, 보스턴의 labcentral 등 글로벌 엑셀러레이터와 같은 역할을 목표로 한다.

Differentiator

Problem solved

Functional benefit

Products and services

• Open Lab and Office Space Provision

Named customers10 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered minor, core and reference.

• GE헬스케어 코리아 (GE Healthcare Korea)minorStrategic or Co-development Partner · 1 July 2024MOU signed between GE Healthcare Korea and portfolio company Supernova Bio for obesity treatment solution development. GE Healthcare provides ultrasound diagnostic medical device technical support while Supernova Bio provides local fat-dissolving agent and market development for next-generation aesthetic treatment market.
• 서울경제진흥원, 한국중견기업연합회, 한국표준협회minorGTM or Marketing Partner · 1 January 2024Co-organized 2024 I AM Challenge as investment co-recruiting institution. InnoCube participated as bio healthcare sector investor to discover startups with innovative ideas and technologies.
• 크리액티브헬스 (CreActive Health)coreStrategic or Co-development Partner · 1 July 2023Bio healthcare venture studio partnership for potential company discovery, evaluation, investment, incubation, and development. First investment of 300 million KRW made in portfolio company Supernova Bio. Supernova Bio, D.R. Nano, and CAH POC lab moved into InnoCube Open Innovation Center.
• 연세대학교 바이오헬스기술지주회사 (Yonsei Bio-health Technology Holding)coreStrategic or Co-development PartnerStrategic partner for joint bio healthcare startup competitions and venture fund formation. Collaborated on Sevrance-InnoCube Bio Healthcare Competition to identify promising startups. Jointly operates 90 billion KRW venture investment fund.
• 한독 퓨쳐 콤플렉스 (Handok Future Complex)coreOthersState-of-the-art R&D facility completed in May 2022 with approximately 21,837m2 floor area. Houses InnoCube headquarters, Handok R&D center. Features include gardens on 1st and 3rd floors, eco-friendly design, and won 2023 Korea Ecology and Architecture Award (Environment Minister Award).
• 이스라엘 FutuRxreferenceStrategic or Co-development PartnerIsraeli bio incubator serving as reference model for InnoCube's accelerator operations. Provides access to global biotech ecosystem and networking opportunities for portfolio companies.
• 서울홍릉강소특구minorStrategic or Co-development PartnerCo-hosted competition with Seoul Hongneung Bio Special Zone to support growth of promising bio healthcare companies. Provided up to 500 million KRW investment discussions, TIPS support, research equipment, infrastructure, and networking opportunities with Handok.
• 서울대병원, 한독 과학자문위원회coreStrategic or Co-development PartnerScientific Advisory Board (SAB) shared with Handok includes experts from Seoul National University Hospital (김범석, 김주한), KAIST (신의철), Seoul National University (박승범). Provides technology evaluation and development advisory for portfolio companies.

Scale indicators9 records

Recent moves10 records

Expansion highlights5 records

Direct peers

• BioLabs: Operator of shared, fully-equipped co-working laboratory facilities for early-stage life sciences companies across multiple U.S. and European cities. Directly comparable to Innocuve's shared Open Lab / equipment-room offering for resident bio startups.
• FutuRx: Israel-based biotech accelerator that Innocuve explicitly cites as a reference model. Operates a similar shared-lab, milestone-based incubation model for early-stage bio startups, making it the most directly comparable peer in mission and operating mechanics.
• LabCentral: Boston-based biotech incubator with shared laboratory and office infrastructure for resident startups. Innocuve references LabCentral as a model for its Open Lab and shared research facilities, indicating very similar operating concept and target customer.
• IndieBio: Bay Area-based bio-focused accelerator running cohort-based programs for early-stage life sciences startups with shared lab access and seed investment. Closely matches Innocuve's science-to-commercialization model and biotech-only thesis.

Broad incumbents

• Johnson & Johnson Innovation — JLABS: Global no-strings-attached biotech incubator network run by J&J. Innocuve explicitly names J&J Jlabs as a reference model, but JLABS operates at much larger global scale as part of a multinational pharma, making it a broader incumbent comparison.
• Novo Nordisk Foundation BioInnovation Institute (BII): Copenhagen-based biotech incubator/accelerator funded by the Novo Nordisk Foundation. Larger, well-capitalized institution offering biotech venture programs (Creation House, Bio Studio) analogous to Innocuve's lab-plus-funding model.
• Bayer Co.Lab: Global biotech incubator network run by Bayer Pharma supporting early-stage life sciences companies with infrastructure and partnership access. Comparable in pharma-affiliated accelerator structure, though operating at multinational scale.
• Roche Pharma Partnering & Innovation: Roche's partnering and innovation function incubates and partners with early-stage therapeutic ventures globally. Comparable as a pharma-corporate-sponsored bio accelerator, though embedded within a global top-tier pharmaceutical company rather than a standalone entity.
• OrbiMed: Global healthcare-dedicated investment firm managing multiple venture and growth-equity funds across biotech, medtech, and diagnostics. Comparable in healthcare-focused investment management, though operating at significantly larger AUM and stage breadth than Innocuve.
• ARCH Venture Partners: Long-tenured U.S. early-stage life sciences venture firm that has incubated multiple breakthrough biotech companies. Comparable in deep-science, early-stage bio investing orientation, though at materially larger fund and portfolio scale than Innocuve.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Innocube